Ta strona została przetłumaczona automatycznie i dokładność tłumaczenia nie jest gwarantowana. Proszę odnieść się do angielska wersja za tekst źródłowy.

A Study of Ramantamig in Combination With Daratumumab With or Without Lenalidomide or of Single-agent JNJ-102299639 for Multiple Myeloma, Newly Diagnosed AL Amyloidosis, and High-risk Smoldering Multiple Myeloma or Ramantamig in Combination With Pomalidomide for Multiple Myeloma (TRIlogy-2)

13 listopada 2026 zaktualizowane przez: Janssen Research & Development, LLC

A Phase 1b Study of Ramantamig in Combination With Daratumumab With or Without Lenalidomide or of Single-agent JNJ-102299639 for Multiple Myeloma, Newly Diagnosed AL Amyloidosis, and High-risk Smoldering Multiple Myeloma or Ramantamig With Pomalidomide for Multiple Myeloma

The primary purpose of this study for Part 1 (Dose Escalation) is to identify the safe effective dose (recommended Phase 2 doses [RP2Ds]) and schedule for ramantamig treatment regimens and JNJ-102299639 treatment regimens; and for Part 2 (Dose Expansion) is to further characterize the safety and tolerability of ramantamig and JNJ-102299639 treatment regimens at selected RP2D(s).

Przegląd badań

Status

Rekrutacyjny

Warunki

Interwencja / Leczenie

Typ studiów

Interwencyjne

Zapisy (Szacowany)

280

Faza

  • Faza 1

Kontakty i lokalizacje

Ta sekcja zawiera dane kontaktowe osób prowadzących badanie oraz informacje o tym, gdzie badanie jest przeprowadzane.

Kontakt w sprawie studiów

Lokalizacje studiów

      • Clayton, Australia, 3168
        • Rekrutacyjny
        • Monash Medical Centre
      • Fitzroy, Australia, 3065
        • Rekrutacyjny
        • St Vincents Hospital Melbourne
      • Melbourne, Australia, 3000
        • Rekrutacyjny
        • Peter MacCallum Cancer Centre
      • Waratah, Australia, 2298
        • Rekrutacyjny
        • Calvary Mater Newcastle Hospital
      • Wollongong, Australia, 2500
        • Rekrutacyjny
        • Wollongong Hospital
      • Barcelona, Hiszpania, 08036
        • Rekrutacyjny
        • Hosp. Clinic de Barcelona
      • Salamanca, Hiszpania, 37007
        • Rekrutacyjny
        • Hosp Clinico Univ de Salamanca
      • Amsterdam, Holandia, 1081 HV
        • Rekrutacyjny
        • VU Medisch Centrum
      • Groningen, Holandia, 9713 GZ
        • Rekrutacyjny
        • Universitair Medisch Centrum Groningen
      • Utrecht, Holandia, 3584 CX
        • Rekrutacyjny
        • UMC Utrecht
      • Haifa, Izrael, 3436212
        • Rekrutacyjny
        • Carmel Medical Center
      • Ramat Gan, Izrael, 52621
        • Rekrutacyjny
        • Sheba Medical Center
      • Tel Aviv, Izrael, 64239
        • Rekrutacyjny
        • Tel Aviv Sourasky Medical Center
      • Yeruham, Izrael, 9112001
        • Rekrutacyjny
        • Hadassah Medical Center
    • Colorado
      • Denver, Colorado, Stany Zjednoczone, 80218
        • Rekrutacyjny
        • Colorado Blood Cancer Institute
    • Georgia
      • Atlanta, Georgia, Stany Zjednoczone, 30322
        • Rekrutacyjny
        • Winship Cancer Institute Emory University

Kryteria uczestnictwa

Badacze szukają osób, które pasują do określonego opisu, zwanego kryteriami kwalifikacyjnymi. Niektóre przykłady tych kryteriów to ogólny stan zdrowia danej osoby lub wcześniejsze leczenie.

Kryteria kwalifikacji

Wiek uprawniający do nauki

18 lat i starsze (Dorosły, Starszy dorosły)

Akceptuje zdrowych ochotników

Nie

Płeć kwalifikująca się do nauki

Wszystko

Opis

Inclusion Criteria for newly diagnosed multiple myeloma (NDMM) and relapsed or refractory multiple myeloma (R/R MM):

  • Have documented initial diagnosis of multiple myeloma according to IMWG diagnostic criteria
  • Meet treatment regimen-specific requirements as follows: Treatment regimen A (ramantamig+daratumumab):Treatment regimens A1 and A3: Have been treated with 1 to 3 prior lines of therapy, including a proteasome inhibitor (PI) and an inhibitor, immunomodulatory drug (IMiD) therapy for the treatment of multiple myeloma (MM); Treatment regimens A2 and A4: Newly diagnosed MM naïve to multiple myeloma (or other related plasma cell neoplasm)-directed treatments; Treatment regimen B (ramantamig+pomalidomide): Have received greater than or equal to (>=) 1 prior line of therapy, including a PI and lenalidomide, and are lenalidomide refractory OR >=2 prior lines of therapy, including a PI and lenalidomide; Treatment Regimens C, D, E and H: Newly diagnosed MM naïve to multiple myeloma (or other related plasma cell neoplasm)-directed treatments
  • Have a weight >=40 kilograms
  • Must have an Eastern Cooperative Oncology Group status of 0 or 2
  • Have measurable disease at screening as defined by at least 1 of the following: a) Serum monoclonal protein (M-protein) level >= 0.5 gram per deciliter (g/dL); or b) Urine M-protein level >=200 milligram (mg)/24 hours; or c) Light chain multiple myeloma: Serum immunoglobulin (Ig) free light chain (FLC) >= 10 mg/dL and abnormal serum Ig kappa lambda FLC ratio. d) For participants without measurable disease in the serum, urine, or involved FLC: presence of 1 or more focus of extramedullary disease which meets the following criteria: extramedullary plasmacytoma not contiguous with a bone lesion, at least 1 lesion >=2 centimeter (cm) (at its greatest dimension) diameter on whole body positron emission tomography-computed tomography (or whole-body magnetic resonance imaging approved by sponsor), and not previously radiated

Inclusion criteria for newly diagnosed amyloid light chain (ND AL) Amyloidosis

  • Have a histopathological diagnosis of amyloidosis
  • Have an ECOG performance status of 0 to 1

Inclusion criteria for High-risk smoldering multiple myeloma (SMM)

  • Have a diagnosis of SMM (per IMWG criteria) for less than or equal to (<=) 5 years with measurable disease at the time of enrollment as defined in the protocol
  • Have an ECOG performance status of 0 to 1

Exclusion Criteria for NDMM and R/R MM:

  • Prior antitumor therapy as follows, in the specified time frame prior to the first dose of study treatment: a) Targeted therapy, epigenetic therapy, monoclonal antibody (mAb) treatment, or treatment with an investigational drug or an invasive investigational medical device within 21 days or 5 half-lives, whichever is less. b) Gene-modified adoptive cell therapy (example, chimeric antigen receptor [CAR] modified T cells, natural killer cells) within 90 days. c) Prior anti-CD38 directed therapy within 90 days (for treatment regimens A, C, D and E only; within 21 days for treatment regimen B). d) Conventional chemotherapy within 21 days. e) PI therapy within 14 days. f) Immunomodulatory agent therapy within 7 days. g) Radiotherapy within 14 days
  • Stem cell transplantation: a) Allogeneic stem cell transplant within 6 months before the first dose of study treatment. b) Received an autologous stem cell transplant <=12 weeks before the first dose of study treatment
  • Nonhematologic toxicity from prior anticancer therapy that has not resolved to baseline level or to grade <=1 (except alopecia, tissue post-RT fibrosis [any grade] or peripheral neuropathy grade <=3)
  • Prior treatment with CD3-redirecting therapy

Exclusion Criteria for ND AL Amyloidosis

  • Previous or current diagnosis of symptomatic multiple myeloma, including the presence of lytic bone disease, plasmacytomas, >=60 percent (%) plasma cells in the bone marrow, or hypercalcemia
  • Macroglossia that impairs swallowing difficulty
  • Prior therapy for AL amyloidosis or multiple myeloma

Exclusion Criteria for High-risk SMM

  • Multiple myeloma, requiring treatment
  • Primary systemic AL (immunoglobulin light chain) amyloidosis

Exclusion criteria for all participants:

  • Any serious underlying medical conditions, such as: Evidence of active viral, bacterial, or systemic fungal infection requiring ongoing antiviral, antibacterial, or antifungal treatment; active autoimmune disease requiring systemic immunosuppressive therapy within 6 months before start of study treatment; cardiovascular dysfunction; pulmonary compromise requiring supplemental oxygen use to maintain adequate oxygenation; human immunodeficiency (HIV) infection; active hepatitis B or C infection; stroke or seizure within 6 months prior to first dose of study treatment
  • Known or suspected chronic obstructive pulmonary disease (COPD) with a forced expiratory volume in 1 second (FEV1) less than (<) 50 percent (%)

Plan studiów

Ta sekcja zawiera szczegółowe informacje na temat planu badania, w tym sposób zaprojektowania badania i jego pomiary.

Jak projektuje się badanie?

Szczegóły projektu

  • Główny cel: Leczenie
  • Przydział: Nielosowe
  • Model interwencyjny: Zadanie sekwencyjne
  • Maskowanie: Brak (otwarta etykieta)

Broń i interwencje

Grupa uczestników / Arm
Interwencja / Leczenie
Eksperymentalny: Treatment Regimen A and C: Ramantamig+Daratumumab

Participants who have received 1-3 prior lines of therapy, including a proteasome inhibitor (PI) and an immunomodulatory drug (IMiD) (Treatment regimen A1 and A3) will receive ramantamig along with daratumumab to establish the recommended phase 2 doses (RP2D[s]) of the ramantamig during Part 1 (Dose Escalation) of the study. Based on the study evaluation team (SET) decision, enrollment may proceed in participants with newly diagnosed multiple myeloma (NDMM) (Treatment regimens A2, A4 and C). Dose escalation and de-escalation will be based on SET evaluation. In Part 2 (Dose Expansion) participants will receive a dose of ramantamig combination treatment regimen(s) at the RP2D(s) determined in Part 1 and in disease subgroup(s) to determine the safety and tolerability of the combination treatment regimens.

Daratumumab will be administered subcutaneously.

Ramantamig will be administered subcutaneously.

Eksperymentalny: Treatment Regimen B: Ramantamig+Pomalidomide

Participants who have received greater than or equal to (>=)1 prior line of therapy, including a PI and lenalidomide, and are lenalidomide refractory or >=2 prior lines of therapy, including a PI and lenalidomide will receive ramantamig along with pomalidomide to establish the RP2D(s) of the ramantamig during Part 1 (Dose Escalation) of the study. Dose escalation and de-escalation will be based on SET evaluation. In Part 2 (Dose Expansion) participants will receive a dose of ramantamig combination treatment regimen(s) at the RP2D(s) determined in Part 1 and in disease subgroup(s) to determine the safety and tolerability of the combination treatment regimens.

Pomalidomide will be administered orally.

Ramantamig will be administered subcutaneously.

Eksperymentalny: Treatment Regimen D and E: Ramantamig + Daratumumab + Lenalidomide Combination

Participants with NDMM will receive ramantamig along with daratumumab and lenalidomide to establish the RP2D[s] of the ramantamig during Part 1 (Dose Escalation) of the study. Dose escalation and de-escalation will be based on SET evaluation. In Part 2 (Dose Expansion) participants will receive a dose of ramantamig combination treatment regimen(s) at the RP2D(s) determined in Part 1 and in disease subgroup(s) to determine the safety and tolerability of the combination treatment regimens.

Lenalidomide will be administered orally.

Daratumumab will be administered subcutaneously.

Ramantamig will be administered subcutaneously.

Eksperymentalny: Treatment Regimen F: Ramantamig+ Daratumumab

Participants with newly diagnosed amyloid light chain (ND AL) amyloidosis will receive ramantamig in treatment regimen F along with daratumumab to establish the RP2D[s] of the ramantamig during Part 1 (Dose Escalation) of the study. Dose escalation and de-escalation will be based on SET evaluation. In Part 2 (Dose Expansion) participants will receive a dose of ramantamig and daratumumab at the RP2D(s) determined in Part 1 and in disease subgroup(s) to determine the safety and tolerability of the combination treatment regimens.

Daratumumab will be administered subcutaneously.

Ramantamig will be administered subcutaneously.

Eksperymentalny: Treatment Regimen G: Ramantamig + Daratumumab

Participants with high-risk smoldering multiple myeloma (SMM) will receive ramantamig in treatment regimen G along with daratumumab to establish the RP2D[s] of the ramantamig during Part 1 (Dose Escalation) of the study. Dose escalation and de-escalation will be based on SET evaluation. In Part 2 (Dose Expansion) participants will receive a dose of ramantamig and daratumumab at the RP2D(s) determined in Part 1 and in disease subgroup(s) to determine the safety and tolerability of the combination treatment regimens.

Daratumumab will be administered subcutaneously.

Ramantamig will be administered subcutaneously.

Eksperymentalny: Treatment Regimen H: JNJ-102299639

Participants with NDMM in treatment regimen H will receive JNJ-102299639 to establish the RP2D[s] during Part 1 (Dose Escalation) of the study. Dose escalation and de-escalation will be based on SET evaluation. In Part 2 (Dose Expansion) participants will receive JNJ-102299639 at the RP2D(s) determined in Part 1 and in disease subgroup(s) to determine the safety and tolerability of the treatment regimens.

JNJ-102299639 will be administered subcutaneously.

Eksperymentalny: Treatment Regimen I: JNJ-102299639

Participants with ND AL Amyloidosis in treatment regimen I will receive JNJ-102299639 to establish the RP2D[s] during Part 1 (Dose Escalation) of the study. Dose escalation and de-escalation will be based on SET evaluation. In Part 2 (Dose Expansion) participants will receive JNJ-102299639 at the RP2D(s) determined in Part 1 and in disease subgroup(s) to determine the safety and tolerability of the treatment regimens.

JNJ-102299639 will be administered subcutaneously.

Eksperymentalny: Treatment Regimen J: JNJ-102299639

Participants with high-risk SMM in treatment regimen J will receive JNJ-102299639 to establish the RP2D[s] during Part 1 (Dose Escalation) of the study. Dose escalation and de-escalation will be based on SET evaluation. In Part 2 (Dose Expansion) participants will receive JNJ-102299639 at the RP2D(s) determined in Part 1 and in disease subgroup(s) to determine the safety and tolerability of the treatment regimens.

JNJ-102299639 will be administered subcutaneously.

Co mierzy badanie?

Podstawowe miary wyniku

Miara wyniku
Opis środka
Ramy czasowe
Part 1: Number of Participants with Dose-limiting Toxicity (DLT)
Ramy czasowe: Up to 28 days

DLTs are specific adverse events and are defined as any of the following: high grade non-hematologic toxicity, or hematologic toxicity.

Up to 28 days
Number of Participants with Adverse Events (AEs) by Severity
Ramy czasowe: Up to 3 Years and 3 months

An AE is any untoward medical occurrence in a clinical study participant that does not necessarily have a causal relationship with the pharmaceutical/biological agent under study. Severity will be graded according to the national cancer institute common terminology criteria for adverse events (NCI-CTCAE) version 5.0. Severity scale ranges from grade 1 (mild) to grade 5 (death). Grade 1= mild, Grade 2= moderate, Grade 3= severe, Grade 4= life-threatening and Grade 5= death related to adverse event.

Up to 3 Years and 3 months
Number of Participants with Clinically Significant Laboratory Abnormalities
Ramy czasowe: Up to 3 Years and 3 months

Participants with clinically significant laboratory abnormalities (hematology and chemistry) will be reported.

Up to 3 Years and 3 months

Miary wyników drugorzędnych

Miara wyniku
Opis środka
Ramy czasowe
Percentage of Participants With Overall Response Rate
Ramy czasowe: Up to 3 Years and 3 months

Overall response rate is defined as percentage of participants with newly diagnosed multiple myeloma (NDMM), relapsed or refractory multiple myeloma (R/R MM), or high-risk smoldering multiple myeloma (SMM) who have a partial response (PR) or better evaluated by the investigator as per international myeloma working group (IMWG) 2016 criteria.

Up to 3 Years and 3 months
Percentage of Participants With Very Good Partial Response (VGPR) or Better Response Rate
Ramy czasowe: Up to 3 Years and 3 months

VGPR or better response rate is defined as the percentage of participants with NDMM, R/R MM, or high-risk SMM who achieve a VGPR or better response (stringent complete response [sCR]+ complete response [CR]+VGPR) according to the IMWG 2016 criteria.

Up to 3 Years and 3 months
Percentage of Participants With CR or Better Response Rate
Ramy czasowe: Up to 3 Years and 3 months

CR or better response rate is defined as the percentage of participants with NDMM R/R MM, or high-risk SMM who achieve a CR or better response (sCR+CR) according to the IMWG 2016 criteria.

Up to 3 Years and 3 months
Percentage of Participants With sCR or Better Response Rate
Ramy czasowe: Up to 3 Years and 3 months

sCR rate is defined as the percentage of participants with NDMM R/R MM, or high-risk SMM who achieve an sCR according to the IMWG 2016 criteria.

Up to 3 Years and 3 months
Duration of Response (DOR)
Ramy czasowe: Up to 3 Years and 3 months

DOR is defined as time from date of initial documentation of a response (PR or better) to date of first documented evidence of progressive disease (PD), as per IMWG 2016 response criteria, or death due to progression, whichever occurs first in participants with NDMM, R/R MM, or high-risk SMM.

Up to 3 Years and 3 months
Time to Response (TTR)
Ramy czasowe: Up to 3 Years and 3 months

TTR is defined as the time between date of first dose of study treatment and the first efficacy evaluation at which the participants with NDMM, R/R MM, or high-risk SMM has met all criteria for PR or better as defined by IMWG 2016 response criteria.

Up to 3 Years and 3 months
Percentage of Participants With Hematologic Response As Defined by International Amyloidosis Consensus Criteria
Ramy czasowe: Up to 3 Years and 3 months

Hematologic response is defined as percentage of participants with newly diagnosed amyloid light chain (ND AL) amyloidosis who achieve complete response, very good partial response, partial response, no response and progression as defined by International amyloidosis consensus criteria present in the protocol will be reported.

Up to 3 Years and 3 months
DOR as Defined by International Amyloidosis Consensus Criteria
Ramy czasowe: Up to 3 Years and 3 months

DOR is defined as time from date of initial documentation of a response (PR or better) to date of first documented evidence of progressive disease (PD), as per International amyloidosis consensus criteria, or death due to progression, whichever occurs first in participants with ND AL amyloidosis.

Up to 3 Years and 3 months
TTR as Defined by International Amyloidosis Consensus Criteria
Ramy czasowe: Up to 3 Years and 3 months

TTR is defined as the time between date of first dose of study treatment and the first efficacy evaluation at which the participant with ND AL amyloidosis has met all criteria for PR or better as defined by International amyloidosis consensus criteria.

Up to 3 Years and 3 months
Serum Concentration of Ramantamig, Daratumumab, and JNJ-102299639
Ramy czasowe: Up to 3 Years and 3 months

Serum samples will be analyzed to determine concentrations of ramantamig, daratumumab, and JNJ-102299639.

Up to 3 Years and 3 months
Area Under the Serum Concentration Time Curve from Time Zero to Infinity (AUCinf) for Ramantamig, Daratumumab, and JNJ-102299639
Ramy czasowe: Up to 3 Years and 3 months

AUCinf for ramantamig, daratumumab, and JNJ-102299639 will be reported.

Up to 3 Years and 3 months
Area Under the Serum Concentration Time Curve from Time Zero to the Last Measurable Concentration [AUC(0-t)] for Ramantamig, Daratumumab, and JNJ-102299639
Ramy czasowe: Up to 3 Years and 3 months

AUC(0-t) for ramantamig, daratumumab, and JNJ-102299639 will be reported.

Up to 3 Years and 3 months
Area Under the Serum Concentration Time Curve During the Dosing Interval (AUCtau) for Ramantamig, Daratumumab, and JNJ-102299639
Ramy czasowe: Up to 3 Years and 3 months

AUCtau for ramantamig, daratumumab, and JNJ-102299639 will be reported.

Up to 3 Years and 3 months
Maximum Serum Concentration (Cmax) for Ramantamig, Daratumumab, and JNJ-102299639
Ramy czasowe: Up to 3 Years and 3 months

Cmax for ramantamig, daratumumab, and JNJ-102299639 will be reported.

Up to 3 Years and 3 months
Half Life (T1/2) for Ramantamig, Daratumumab, and JNJ-102299639
Ramy czasowe: Up to 3 Years and 3 months

T1/2 for ramantamig, daratumumab, and JNJ-102299639 will be reported.

Up to 3 Years and 3 months
Time to Reach Cmax (Tmax) for Ramantamig, Daratumumab, and JNJ-102299639
Ramy czasowe: Up to 3 Years and 3 months

Tmax for ramantamig, daratumumab, and JNJ-102299639 will be reported.

Up to 3 Years and 3 months
Systemic Clearance (CL/F) for Ramantamig, Daratumumab, and JNJ-102299639
Ramy czasowe: Up to 3 Years and 3 months

CL/F for ramantamig, daratumumab, and JNJ-102299639 will be reported.

Up to 3 Years and 3 months
Apparent Volume of Distribution at Steady State (Vss/F) for Ramantamig, Daratumumab, and JNJ-102299639
Ramy czasowe: Up to 3 Years and 3 months

Vss/F for ramantamig, daratumumab, and JNJ-102299639 will be reported.

Up to 3 Years and 3 months
Number of Participants with Presence of Anti-Drug Antibodies to Ramantamig, Daratumumab, and JNJ-102299639
Ramy czasowe: Up to 3 Years and 3 months

Participants with anti-drug antibodies to ramantamig, daratumumab, and JNJ-102299639 will be reported.

Up to 3 Years and 3 months

Współpracownicy i badacze

Tutaj znajdziesz osoby i organizacje zaangażowane w to badanie.

Sponsor

Śledczy

  • Dyrektor Studium: Janssen Research & Development, LLC Clinical Trial, Janssen Research & Development, LLC

Publikacje i pomocne linki

Osoba odpowiedzialna za wprowadzenie informacji o badaniu dobrowolnie udostępnia te publikacje. Mogą one dotyczyć wszystkiego, co jest związane z badaniem.

Daty zapisu na studia

Daty te śledzą postęp w przesyłaniu rekordów badań i podsumowań wyników do ClinicalTrials.gov. Zapisy badań i zgłoszone wyniki są przeglądane przez National Library of Medicine (NLM), aby upewnić się, że spełniają określone standardy kontroli jakości, zanim zostaną opublikowane na publicznej stronie internetowej.

Główne daty studiów

Rozpoczęcie studiów (Rzeczywisty)

4 grudnia 2024

Zakończenie podstawowe (Szacowany)

2 stycznia 2029

Ukończenie studiów (Szacowany)

29 czerwca 2029

Daty rejestracji na studia

Pierwszy przesłany

23 grudnia 2024

Pierwszy przesłany, który spełnia kryteria kontroli jakości

9 stycznia 2025

Pierwszy wysłany (Rzeczywisty)

10 stycznia 2025

Aktualizacje rekordów badań

Ostatnia wysłana aktualizacja (Rzeczywisty)

17 listopada 2026

Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości

13 listopada 2026

Ostatnia weryfikacja

1 listopada 2026

Więcej informacji

Terminy związane z tym badaniem

Plan dla danych uczestnika indywidualnego (IPD)

Planujesz udostępniać dane poszczególnych uczestników (IPD)?

TAK

Opis planu IPD

The data sharing policy of Johnson & Johnson Innovative Medicine is available at innovativemedicine.jnj.com/our-innovation/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu

Informacje o lekach i urządzeniach, dokumenty badawcze

Bada produkt leczniczy regulowany przez amerykańską FDA

Tak

Bada produkt urządzenia regulowany przez amerykańską FDA

Nie

produkt wyprodukowany i wyeksportowany z USA

Tak

Te informacje zostały pobrane bezpośrednio ze strony internetowej clinicaltrials.gov bez żadnych zmian. Jeśli chcesz zmienić, usunąć lub zaktualizować dane swojego badania, skontaktuj się z register@clinicaltrials.gov. Gdy tylko zmiana zostanie wprowadzona na stronie clinicaltrials.gov, zostanie ona automatycznie zaktualizowana również na naszej stronie internetowej .